Blood · 1995 · 117 citations · 40 references
Life SciencesImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentAntitumor T Cell ResponsesCytokines In Tumor ImmunityCytotoxic T Lymphocyte ResponsesHumoral ImmunityImmune ResponseMyeloid-derived Suppressor CellsB7 Family Immunoregulatory Ligands
A costimulatory signal from B7-1 (CD80) to its counter-receptor CD28 is required for T-cell activation. Many tumors, including most human leukemias, lack expression of B7-1, and this has been suggested to contribute to the failure of immune recognition of these diseases. A murine leukemia model system was developed to assess the potential role of B7-1 in the induction immunity to leukemia cells. The nonleukemic 32Dc13 myeloid cell line was transformed by transfection of the BCR/ABL gene, generating a subline (32Dp210/clone 26) that was leukemic and rapidly lethal to syngeneic, immunocompetent C3H/HeJ mice or T-cell-deficient nude mice. B7-1-modified leukemic cells remained lethal in nude mice, but caused only a transient, nonlethal leukemia in C3H/HeJ mice. After a single exposure to live, nonirradiated B7-1-modified leukemic cells, C3H/HeJ mice developed protective immunity against subsequent challenge with B7-1(-) leukemic cells. Further, hyperimmunization with B7-1(+) leukemic cells prolonged the survival of mice previously injected with a lethal number of B7-1(-) leukemic cells. These results indicate that myeloid leukemic cells may be attractive candidates for B7-1 gene transfer.
40
Glen Dranoff, Elizabeth M. Jaffee, A Lazenby et al. · Proceedings of the National Academy of Sciences · 1993 · 2.8K citations
Medicine, Immunology, Oncology +17
A Cell Culture Model for T Lymphocyte Clonal Anergy
Ronald H. Schwartz · Science · 1990 · 1.9K citations
CTLA-4 is a second receptor for the B cell activation antigen B7.
Peter S. Linsley, William Brady, M Urnes et al. · The Journal of Experimental Medicine · 1991 · 1.7K citations · Full text